secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2026-10-20T11:00:43+00:00
Accession:  0001140361-26-040177
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Insmed adds ex-Sanofi CEO Paul Hudson and Verily CFO Utpal Koppikar to board
----------------------------------------------------------------------------

- Board appointed Paul Hudson and Utpal Koppikar as independent directors effective Oct 19, 2026; Hudson is Class II, Koppikar Class I, both up for election at the 2027 annual meeting.
- Hudson was Sanofi CEO from September 2019 to February 2026 and CEO of Novartis Pharmaceuticals from 2016 to 2019; he joins the Compensation Committee.
- Koppikar has been Verily Health CFO since April 2023, was EVP and CFO of Atara Biotherapeutics from 2018 to 2023, and sits on C4 Therapeutics' (CCCC) board; he joins the Audit Committee.
- Each director gets a $65,000 annual retainer plus $12,500 for committee service, prorated, and RSUs worth about $585,000 vesting in three equal annual installments.
- Insmed said there are no arrangements or Item 404(a) related-party transactions involving either new director; CEO Will Lewis called it a strengthened board at a pivotal time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126040177/0001140361-26-040177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036126040177/ef20084030_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-040177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer